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Aims: Drug disposition in children may vary from adults due to age‐related varia-
tion in drug metabolism. Microdose studies present an innovation to study pharmaco-
kinetics (PK) in paediatrics; however, they should be used only when the PK is dose
linear. We aimed to assess dose linearity of a [14C]midazolam microdose, by compar-
ing the PK of an intravenous (IV) microtracer (a microdose given simultaneously with
a therapeutic midazolam dose), with the PK of a single isolated microdose.
Methods: Preterm to 2‐year‐old infants admitted to the intensive care unit received
[14C]midazolam IV as a microtracer or microdose, followed by dense blood sampling up
to 36 hours. Plasma concentrations of [14C]midazolam and [14C]1‐hydroxy‐midazolam
were determined by accelerator mass spectrometry. Noncompartmental PK analysis
was performed and a population PK model was developed.
Results: Of 15 infants (median gestational age 39.4 [range 23.9–41.4] weeks, post-
natal age 11.4 [0.6–49.1] weeks), 6 received a microtracer and 9 a microdose of [14C]
midazolam (111 Bq kg−1; 37.6 ng kg−1). In a 2‐compartment PK model, bodyweight
was the most significant covariate for volume of distribution. There was no statisti-
cally significant difference in any PK parameter between the microdose and
microtracer, nor in the area under curve ratio [14C]1‐OH‐midazolam/[14C]midazolam,
showing the PK of midazolam to be linear within the range of the therapeutic and
microdoses.
Conclusion: Our data support the dose linearity of the PK of an IV [14C]midazolam
microdose in children. Hence, a [14C]midazolam microdosing approach may be used
as an alternative to a therapeutic dose of midazolam to study developmental changes
in hepatic CYP3A activity in young children.
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1 | INTRODUCTION
Drug disposition in children may vary from adults due to age‐related
variation in the processes governing absorption, distribution, metab-
olism and excretion.1,2 This variation is largest in the first years of
life and is not directly proportionate to size.3,4 However, in daily
clinical practice, drug dosing in paediatrics is often based on
bodyweight based corrections, which, because of variation arising
from development, can result in subtherapeutic or toxic drug expo-
sure in certain subgroups.2 Hence, doses used for children cannot
simply be extrapolated from adults using a simple bodyweight‐based
correction.
Phenotyping studies, in which model drugs representative for a
certain pathway are studied across the paediatric age range, can be
used to elucidate the age‐related variation in drug disposition path-
ways in vivo.5 However, these studies are faced with ethical, practical
and scientific challenges. Children are vulnerable, and so exposing
them to (almost) therapeutic doses of drugs for a nontherapeutic rea-
son, as in a phenotyping study, may not be ethically acceptable. More-
over, blood sampling for pharmacokinetic (PK) analyses in children is
challenging because of the burden for the individual child, the smaller
blood volume that can be taken, as well as the technical difficulties
associated with sampling.
Microdosing studies present an attractive alternative to overcome
the ethical and analytical challenges of phenotyping studies.6 A
microdose is a very small, subtherapeutic dose of a drug (<1/100th
of the therapeutic dose or <100 μg) that is unlikely to result in phar-
macological effects or adverse events.7,8 A radioactive label [14C]
allows ultrasensitive quantification of extremely low plasma concen-
trations by accelerator mass spectrometry (AMS) for which only 10–
15 μL plasma is required.9,10 The radiation dose associated with a
[14C]microdose is safe as it is below 1 μSievert. This is much lower
than yearly background exposure (2.5 mSv year−1 in The Netherlands),
a computed tomography scan of the head (1200 μSievert), or chest X‐
ray (12 μSievert).6
Microdosing studies can provide unique information on the PK of
drugs in children, and with that valuable information on developmen-
tal changes in drug metabolism pathways, as shown successfully
before.6,11-13 Importantly, a prerequisite is that the PK of a
microdose is linear to the PK of a therapeutic dose.14,15 Lack of line-
arity may occur for example, when a therapeutic dose saturates drug
metabolism pathways, plasma protein binding and/or active trans-
porters, which may result in altered PK when studying a microdose.15
A very elegant approach to study dose linearity is by comparing the
PK parameters of an isolated [14C]microdose with the PK parameters
of a [14C]microtracer, where the labelled microdose is administered
concurrently or even mixed with a therapeutic drug dose.12
Cytochrome P450 (CYP) 3A is a developmentally regulated drug
metabolizing enzyme that is abundant in the liver and accounts for
nearly 46% of the oxidative metabolism of clinically relevant
drugs.1,2,16-21 As midazolam is a well‐established model substrate
for CYP3A activity, this drug may be used for phenotyping studies
using a microdosing approach to elucidate developmental changes
in CYP3A.5,22-25 To the best of our knowledge, dose linearity of the
PK of a microdose to those of a therapeutic dose of midazolam has
been established in adults,14,26,27 but not in children. However, the
results in adults cannot simply be extrapolated to children due to
the development of drug metabolism, hepatic blood flow, protein
binding and drug transport.
We therefore aimed to study the dose linearity of the PK of a
[14C]midazolam microdose in children, by studying the PK parameters
of midazolam when given as an intravenous (IV) [14C]microdose, and
as a [14C]microtracer given simultaneously with a therapeutic mid-
azolam dose.
2 | METHODS
2.1 | Study design
This study was part of the ERA‐NET PRIOMEDCHILD project Paedi-
atric Accelerator Mass Spectrometry Evaluation Research Study
(PAMPER). The 2 units participating in this study were the Alder
Hey Children's NHS Foundation Trust, Liverpool, UK and the Liver-
pool Women's NHS Foundation Trust, Liverpool, UK. Children were
recruited on the paediatric intensive care wards of these units. Ethi-
cal approval was obtained from the Research Ethics Committees for
the hospitals where patients were enrolled. All parents or an adult
who carried parental responsibility provided written informed con-
sent for their child to be included prior to any study‐specific proce-
dures. No radioactive substance administration approval was
required as the administered radioactive dose was below 1 μSievert,
What is already known about this subject
• Microdose studies with radioactive labelled ([14C])
substrates present an innovation to study
pharmacokinetics of drugs in paediatrics
• Dose linearity between the pharmacokinetics of a
microdose and therapeutic dose is an important
prerequisite
• Dose linearity of the pharmacokinetics of a microdose of
[14C]midazolam has not been established in children
What this study adds
• The pharmacokinetics of a microdose of [14C]midazolam
are dose linear to therapeutic doses in children
• As midazolam is a well‐established marker for the
developmentally regulated CYP3A enzyme, a [14C]
midazolam microdosing approach is a minimal risk
strategy to study hepatic CYP3A activity variability in
children
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the UK Administration of Radioactive Substances Advisory Commit-
tee (ARSAC) exemption level.
2.2 | Subjects
Children were eligible to be included in this study from birth up to age
2 years, when they had intravenous lines in place for intravenous
administration, and had suitable vascular access for blood sampling.
Exclusion criteria were serious hepatic impairment (defined by aspar-
tate aminotransferase [ASAT] and alanine aminotransferase
[ALAT] > 200 U L−1) or renal impairment (defined by plasma creatinine
>150 μmol), haemofiltration, peritoneal/haemodialysis or extracorpo-
real membrane oxygenation.
2.3 | Study procedures
A single [14C]midazolam (111 Bq kg−1; 37.6 ng kg−1) dose was admin-
istered IV either as a microtracer during therapeutic midazolam infu-
sion or as an isolated microdose (Figure 1). The microtracer was
mixed with the first therapeutic loading dose of midazolam given by
the treating physician for sedation, and was administered over
30 min. The microdose was administered with a similar infusion rate
to ensure similar exposure to [14C]levels. The IV therapeutic midazo-
lam dose was prescribed by the treating physician for clinical purposes
according to British National Formulary for Children dosing guidelines.
Blood samples were taken before and up to 36 hours after administra-
tion of the [14C]midazolam microtracer or microdose. The time points
for blood sampling were based on the PK of midazolam in paediatric
ICU patients where a median half‐life of 5.5 hours was found.28 To
ensure complete sampling of a single dose, at least 5 times the half‐life
was taken. Moreover, to capture the distribution, metabolism and
elimination phases, the sampling times were set at predose, and
0.17, 0.5, 1, 2, 4, 6, 10, 24 and 36 hours post‐IV dose. The maximum
number of study specific blood samples was limited to 6 per subject.
The specific time points for each patient were decided based on
discussion between the research team, clinical team and parents to
ensure cares were coordinated at this time and with minimal disrup-
tion to the patients' routine. The maximum amount of blood could
not exceed the guidelines by European Medicines Agency (up to 1%
of calculated circulating blood volume).29 The blood samples were
centrifuged and plasma was stored at −80°C until analysed.
2.4 | Radiopharmaceutical preparation
[14C]midazolam was synthesized by Selcia Ltd. (Ongar, Essex, UK) at a
specific activity of 1072 MBq mmol−1 (equal to 2.95 MBq mg−1). The
chemical name is 8‐chloro‐6‐(2‐fluorophenyl)‐1‐methyl‐4H‐[1‐14C]
imidazo[l,5‐a][l,4]benzodiazepine hydrochloride. In the Radiopharmacy
Department, Addenbrookes Hospital, Cambridge, UK under aseptic
conditions, [14C]midazolam was brought in ethanol 96% solution, the
activity was measured and the solution was further diluted 10 000
fold in 5% w/v dextrose solution to the required concentration. The
final solution was filter sterilized (pore size 0.2 μm) and batched for
intravenous injection. The final [14C]midazolam concentration was
500 Bq mL−1.
2.5 | [14C]midazolam and [14C]1‐hydroxy‐midazolam
plasma concentration analysis
2.5.1 | Plasma sample extraction and
ultraperformance liquid chromatography separation
Methanol (10 μL) was added to plasma samples in order precipitate
proteins and to extract the test substance using protein precipitation
plates. Each run consisted of samples measured once and eight cali-
brator levels in duplicate plus 3 different Quality control (QC) levels
in duplicate. The extract was evaporated to dryness, re‐dissolved
and analysed using ultraperformance liquid chromatography. The frac-
tion where midazolam and 1‐hydroxy‐midazolam eluted from the col-
umn was collected for each sample, transferred to a tin foil cup,
evaporated to dryness and subsequently analysed using Combustion‐
CO2‐AMS.
2.5.2 | AMS analysis
[14C] levels were quantified as described before.13,30 The
ultraperformance liquid chromatography and AMS qualification were
performed in accordance with the recommendation of the European
Bioanalytical Forum.31 The tin foil cups (see 2.5.1) were combusted
on an elemental analyser (Vario Micro; Elementar, Langenselbold, Ger-
many). Generated CO2 was transferred to a home‐built gas interface,
composed of a zeolite trap and syringe.30 CO2 was adsorbed to the
trap on the interface; and after heating of the trap, the CO2 was trans-
ferred to a vacuum syringe using helium. A final CO2/helium mixture
of 6% was directed to the AMS ion source, at a pressure of 1 bar
and a flow of 60 μL min−1. A 1‐MV Tandetron AMS (High Voltage
FIGURE 1 Explanation of the terms intravenous microdose and
microtracer midazolam
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Engineering Europe B.V., Amersfoort, The Netherlands)32 was used.
The lower limit of quantification was 0.31 mBq mL−1.
2.6 | Patient characteristics
Patient characteristics (age, weight) and patient laboratory values (cre-
atinine, total bilirubin, ASAT, ALAT) were described using standard
statistics, and data was presented as median (range). Microtracer and
microdosing groups were compared using Mann–Whitney test, as data
were not distributed normally.
2.7 | PK analysis
2.7.1 | Exploration of the data
The data were first explored by visualization of time–concentration
profiles of [14C]midazolam and [14C]1‐hydroxy‐midazolam (GraphPad
Prism 5). Next, their area under the curve (AUC) and the ratio AUC
[14C]1‐hydroxy‐midazolam/[14C]midazolam were estimated using a
log‐linear noncompartmental model (Excel PKSolver add‐in soft-
ware33) and compared between microdose and microtracer adminis-
tration using Mann–Whitney U test.
2.7.2 | Nonlinear mixed effects modelling
[14C]midazolam concentration–time data were analysed using the
nonlinear mixed effects modeling software NONMEM version 7.4
(ICON; Globomax LLC, Ellicott, MD). Model development was in 4
steps: (i) selection of a structural model; (ii) selection of an error
model; (iii) covariate analysis, and (iv) internal validation of the
model.
For model selection, we used the objective function value (OFV)
and standard goodness of fit plots. For the OFV, a drop of more than
3.84 points between nested models was considered statistically
significant, which corresponds to P < .05 assuming a χ2 distribu-
tion.34,35 For the structural and error models, a decrease in OFV of
3.84 points was considered statistically significant (P < .05). For the
structural model, 1‐, 2‐ and 3‐compartment models were tested. Inclu-
sion of log‐normally distributed interindividual variability (IIV) was
tested on all model parameters. For the residual unexplained variabil-
ity additive, proportional and a combination of additive and propor-
tional error model were tested. The continuous covariates evaluated
were postnatal age, postmenstrual age, bodyweight, creatinine, ALAT,
ASAT and total bilirubin. Categorical covariates included treatment
arm (i.e. microdosing or microtracer administration) only. All covariates
were tested on all model parameters. Potential covariates were evalu-
ated using forward inclusion and backward elimination with a level of
significance of <.005 (ΔOFV < −7.9 points) and <.001 (ΔOFV > 10.8
points), respectively. In addition, inclusion of a covariate in the model
had to result in a decline in unexplained IIV and/or improved goodness
of fit plots before it was included in the final model.36 Next, the model
was internally validated using bootstrap analysis in Perl‐speaks‐
NONMEM.
2.8 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corre-
sponding entries in http://www.guidetopharmacology.org, the com-
mon portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY,37 and are permanently archived in the Concise
Guide to PHARMACOLOGY 2017/18.38
3 | RESULTS
3.1 | Subjects and data
Fifteen infants (gestational age 39.4 [23.9–41.4] weeks, postnatal age
11.4 [0.6–49.1 weeks]) were included in the study, of whom 9 received






Number of patients 15 9 6 ‐
Number of samples 67 37 30 ‐
Samples per patient (n) 5 (2–5) 5 (2–5) 5 (5–5) ‐
Gestational age (wk) 39.4 (23.9–41.4) 39.4 (23.9–41.4) 38.4 (26.7–41.0) .15
Postnatal age (weeks) 11.4 (0.6–49.1) 11.4 (0.6–49.1) 13.4 (2.6–42.3) .39
Weight (kg) 3.6 (2.6–8.9) 3.5 (2.7–8.9) 3.8 (2.6–6.0) 1.00
Plasma creatinine (μmol L−1) 35 (20–51) 41 (29–51) 33 (20–36) .07
Total bilirubin (μmol L−1) 9 (2–274) 9 (5–274) 9 (2–146) .46
ASAT (U L−1) 42 (12–93) 41 (12–93) 57 (25–85) .39
ALAT (U L−1) 17 (7–68) 15 (7–43) 23 (16–68) .09
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a microdose and 6 a microtracer of [14C]midazolam. SeeTable 1 for the
patient characteristics. There were no significant differences found
between characteristics of the microdose and microtracer group.
The complete dataset included data on 67 blood samples. Eight
measurements had [14C]midazolam concentrations under the AMS
detection limit and were not included in the analysis.39
3.2 | Exploration of the data
The time–concentration profiles of [14C]midazolam and [14C]1‐
hydroxy‐midazolam of the individual subjects are depicted in
Figure 2 and 3. In Table 2 the individual AUCs and ratio AUC0–t
[14C]1‐hydroxy‐midazolam/[14C]midazolam of the microdose and
FIGURE 2 Individual (n = 9) semilog plasma concentration–time profiles of [14C]midazolam and [14C]1‐hydroxy‐midazolam after administration
of a [14C]midazolam microdose
FIGURE 3 Individual (n = 6) semilog plasma concentration–time profiles of [14C]midazolam and [14C]1‐hydroxy‐midazolam after administration
of a [14C]midazolam microtracer
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microtracer are presented. There were no significant differences
found between the 2 groups.
3.3 | Nonlinear mixed effects modelling
A 2‐compartment model described the PK of [14C]midazolam best.
Inclusion of IIV for clearance improved the model statistically signifi-
cantly. A combined error model was superior over a proportional error
model or an additive error model.
Bodyweight was a significant predictor for the central volume of
distribution and was therefore included in the model. After inclusion
of bodyweight, age and other tested covariates were not found to
be statistically significant. There was a trend for a relation between
bodyweight and clearance, but this did not reach statistical signifi-
cance (ΔOFV ‐4.38).
Inclusion of the covariate treatment (e.g. microtracer or microdose)
upon inclusion on any of the PK parameters was found to not statisti-
cally significantly influence the model fit (ΔOFV >0.01).
The PK parameter estimates of the final model and the bootstrap
results are presented in Table 3. Most RSE values of the parameter
estimates are well below 50%, suggesting that the estimates are pre-
cise. Mean bootstrap values are close to model estimates and 0 is
not in the 95% bootstrap interval, meaning the model is robust.
Figure 4 shows the diagnostic plots for the final model and illustrates
the predictive value of the model for both the microtracer and
microdose group. The figure shows no bias, suggesting that concentra-
tions for both the microdose and the microtracer are accurately pre-
dicted by this model, supporting dose linearity of the microdose.
4 | DISCUSSION
Our study shows dose linearity of the PK of a [14C]midazolam
microdose to the therapeutic dose in children, by the finding that none
of the PK parameters of midazolam were influenced by the treatment
group, i.e. microdose or microtracer [14C]midazolam. A lack of differ-
ence in AUC values for [14C]midazolam and [14C]1‐hydroxy‐midazo-
lam further supports that there is no difference between the PK of a
microtracer and microdose.
TABLE 2 Area under the curve (AUC) of [14C]midazolam and [14C]1‐hydroxy‐midazolam after administration of a microdose or microtracer [14C]
midazolam, presented as median (range)







−1 *h) 46.77 (32.42–196.77) 46.77 (32.42–196.77) 48.28 (39.17–81.40) .86
AUC0–∞ (ng L
−1 *h) 48.90 (34.15–218.80) (n = 14a) 48.90 (34.15–218.80) (n = 8a) 49.11 (39.75–82.45) .66
[14C]1‐hydroxy‐midazolam
AUC0–t (ng L
−1 *h) 10.89 (5.28–24.21) 10.19 (5.28–24.21) 11.20 (5.84–19.93) .86
AUC0–∞ (ng L
−1 *h) 12.39 (5.99–26.41) (n = 14a) 13.14 (7.40–26.41) (n = 8a) 12.39 (5.99–26.27) .95
[14C]1‐hydroxy‐midazolam/ [14C]midazolam
AUC0–t ratio
b 0.23 (0.11–0.51) 0.23 (0.11–0.49) 0.21 (0.13–0.51) .69
afor 1 subject this parameter could not be established as there were only 2 plasma samples available.
bAUC0–t ratio = [
14C]1‐hydroxy‐midazolam AUC0–t/[
14C]midazolam AUC0–t









CL (L h−1) 2.06 (24) 2.23 (1.57–3.23)
Intercompartmental clearance
Q (L h−1) 0.79 (44) 0.90 (0.60–2.45)
Volume of distribution
V1i = V14kg * (WT/4)
k1
̵ V14kg (L) 3.81 (8) 3.75 (3.07–4.66)
̵ k1 1.36 (10) 1.34 (0.68–1.68)
V2 (L) 3.19 (18) 3.30 (2.64–6.41)
Interindividual variability
ω2 CL 0.73 (42) 0.62 (0.13–1.41)
Residual error
Proportional error 0.09 (24) 0.08 (0.05–0.14)
Additional error 0.08 (50) 0.07 (0.01–0.20)
CL = population predicted clearance; Q = intercompartmental clearance;
V1i = individual predicted volume of distribution in the central compart-
ment for individual i; V14kg = population value for volume of distribution
in the central compartment at 4 kg; WT = body weight; k1 = exponent
to relate body weight to volume of distribution; V2 = volume of distribu-
tion in the peripheral compartment; ω2 = variance for the interindividual
variability of the parameter mentioned. The bootstrap was based on 50
resampled datasets.
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These results are in line with the findings in adults (n = 6), where
dose linearity of a 100 μg [14C]midazolam microdose was assessed
in a cross‐over design with 3 treatment regimens.14 The subjects were
administered (i) an oral microdose, (ii) an IV microdose or (iii) a simulta-
neous dose of an IV microtracer with a therapeutic nonradiolabelled
oral dose. Like our results, no difference in IV disposition of midazolam
was found when given as a microdose alone or in presence of a ther-
apeutic dose.
Previously, studies have reported the midazolam PK in paediatrics
after a single IV administration.40-42 Clearance in our study was found
to be 2.06 L h−1 for an infant of 4 kg (equal to 8.6 mL kg−1 min−1). In
preterm infants, the clearance was reported to be lower (median 1.8
[range 0.7–6.7] mL kg−1 min−1)40 reflecting that CYP3A activity is less
mature in preterm infants than in an infant of 4 kg. A study with crit-
ically ill children reported a clearance of 1.11 L h−1 for an infant of 5 kg
(equal to 3.7 mL kg−1 min−1),43 which is lower than in our population.
This paper concludes that inflammation (reflected by high C‐reactive
protein concentrations) and/or number of failing organs influenced
midazolam clearance, possibly as a result of reduced CYP3A activity.43
The lower clearance can probably be explained by the fact that this
study included patients with a higher inflammation‐state and/or more
failing organs, as subjects in the current study were only eligible when
renal‐ or hepatic failure was absent. This is further evidenced by 2
studies investigating a 0.15 mg kg−1 dose in healthy children, where
clearance was found to be similar (3–10 year old, clearance mean ± SD
9.11 ± 1.21 mL kg−1 min−1)42 and slightly higher (0.5–2 year, clearance
11.3 ± 6.3 mL kg−1 min−1)41 than in our population.
Regulatory authorities have indicated that microdose studies with
radioactive labelled compounds are an acceptable component of drug
development.7,44 However, to the best of our knowledge, this
approach has not been used during paediatric drug development,
despite this study and previous other studies illustrating feasibility
and ethical acceptance in that population.11-13 For paracetamol, the
dose linearity of an oral and IV microdose was successfully assessed
in paediatrics.12 A slightly different approach was taken to study
developmental changes in oral disposition of paracetamol and
FIGURE 4 Diagnostic plots for [14C]midazolam pharmacokinetic model, using different symbols for the different treatments. (A) Observed vs
population predicted [14C]midazolam concentrations. (B) Observed vs individually predicted [14C]midazolam concentrations. (C) Weighted
residuals vs population predicted [14C]midazolam concentration. (D) Weighted residuals vs time. Solid lines represent the line of unity in A and B,
and a value of 0 in C and D. dotted line represent ±1.96 standard deviation, representing the interval in which 95% of the conditional weighted
residual (CWRES) values are expected
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metabolites when an oral microtracer of [14C]paracetamol was admin-
istered together with a therapeutic dose of IV paracetamol.11,13 The
known developmental change from mainly sulfation to
glucuronidation was confirmed, and data were added on intestinal
and hepatic metabolism of paracetamol in a large paediatric age range.
Together with our study, these studies pave the way for microdose
studies to be incorporated into paediatric drug development plans to
explore PK in this vulnerable population.
This study is limited by the lack of information on the severity of
disease and inflammation in these patients and by the wide age range
in which extensive development in drug metabolism and transport
occurs. The effect of age and disease on CYP3A activity increased
the variability in PK of midazolam, possibly obscuring a difference
between the PK of a microtracer and a microdose. However, we
showed that the age range was comparable in both treatment groups,
and we assumed the disease severity was similar in the 2 groups.
Another limitation is that the sample size is relatively small. Neverthe-
less, PK parameters between a microdose and a microtracer were sim-
ilar and compared with literature values. Moreover, in adults, low
sample sizes were used to show dose linearity of midazolam.14
A future perspective more specific to this particular study is that
the results indicate that a [14C]midazolam microdose can be used as
an alternative to a midazolam therapeutic dose to study CYP3A activ-
ity in children. In the case of taking that approach, an attempt can be
made in extrapolating the results to other CYP3A‐substrates and pre-
dict their disposition using a physiologically based pharmacokinetic
modelling approach. Importantly, whether this may be possible will
depend on the characteristics of these substrates, as described by
Calvier et al.45 As a substantial number of clinically relevant drugs
used in children are metabolized by CYP3A,16 this has the potential
to impact the efficacy and safety of drug dosing in paediatrics through
more informed adaptations of dosing regimens to this population.
We conclude that the PK parameters of [14C]midazolam adminis-
tered as a microdose did not differ significantly in young infants from
that of a microtracer. This supports the dose linearity of an IV [14C]
midazolam microdose in children, thus a [14C]midazolam microdosing
approach as an alternative to a therapeutic midazolam dose can be
used to study developmental changes in hepatic CYP3A activity.
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